Goldman Sachs Maintains Buy on Twist Bioscience, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has reaffirmed a Buy rating on Twist Bioscience (NASDAQ:TWST) and increased the price target from $25 to $45.
January 18, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has maintained a Buy rating on Twist Bioscience and raised the price target from $25 to $45, indicating a positive outlook on the stock.
The increase in price target by a reputable investment bank like Goldman Sachs typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100